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Objective: The aim of this study was to examine time trends in the incidence of peptic ulcer 
bleeding and risk factors in a defined geographical area in Norway.
Material and methods: Retrospective data were collected for 306 patients with bleeding peptic 
ulcers admitted to one hospital during the 1985–1986, 1995–1996, and 2007–2008 periods.
Results: The incidence in 1985–1986 was 52/100,000 and in 2007–2008 was 45/100,000. In 
the group aged 20–75 years, the incidence decreased by 54% from 54/100000 in 1985–1986 to 
25/100000 in 2007–2008 (P = 0.001) and increased by 49% in the group aged .75 years from 
272/100000 to 406/100000 (P = 0.0001). The use of aspirin or nonsteroidal anti-inflammatory 
steroid drugs (NSAIDs) was 31% in 1985–1986 and increased to 67% in 2007–2008 (P = 0.004). 
In patients using aspirin or NSAIDs, Helicobacter pylori was present in 73% in 1995–1996 
and in 51% in 2007–2008. H. pylori infection declined from 84% to 52% between 1995–1996 
and 2007–2008.
Conclusions: The incidence rate of peptic ulcer bleeding did not change between 1985–1986 and 
2007–2008, but decreased in the age group #75 years and increased in the age group .75 years. 
The use of low-dose aspirin and NSAIDs increased substantially over time, and H. pylori infec-
tion was still present in 51% of these patients in 2007–2008.
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Introduction
A bleeding gastroduodenal ulcer is a potentially life-threatening condition and may 
represent a major treatment challenge. The H2-receptor antagonists were introduced 
in Norway in the late 1970 for the treatment of peptic ulcer disease and were   followed 
by the proton pump inhibitors (PPIs) in the late 1980s. Eradication regimens for 
  Helicobacter pylori were introduced in south-western Norway in 1992. Effective 
medical treatment for peptic ulcer disease has therefore now been available in this area 
for almost 30 years, and a reduction in the incidence of bleeding peptic ulcers might 
be expected. Studies from the Netherlands1 and Germany2 show a stable incidence of 
ulcer bleeding when comparing the time periods 1993–1994 and 2000, and 1989–1990 
and 1999–2000, respectively. In contrast, a report from Greece shows a 30% decrease 
in the incidence of peptic ulcer bleeding from 1995 to 2005,3 and another study from 
Italy shows a decrease of about 42% from 1983–1985 to 2002–2004.4 Use of aspirin, 
NSAIDs, and the presence of H. pylori infection are recognized as important risk factors 
for ulcer bleeding.5–11 Oral corticosteroid use and current smoking are also reported 
as independent risk factors.12 There is a growing elderly population in Norway with 
an increased intake of low-dose aspirin and NSAIDs. The aim of this study was to Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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analyze time trends in the incidence of peptic ulcer bleeding 
between 1985 and 2008, and to elucidate the associated risk 
factors and symptoms prior to admission. The hypothesis was 
that there would be a time trend of decreased incidence of 
peptic ulcer bleeding in the population, especially in younger 
people due to treatment with H2-antagonists or PPIs, and/or 
eradication of H. pylori. In the elderly, more ulcer   bleeding 
was expected due to a suggested increase in the use of aspirin 
or NSAIDs.
Material and methods
inclusion and diagnosis
Patients aged 20 years or older who had been emergency 
admissions to the surgical or medical department of 
  Haugesund Hospital for acute gastrointestinal (GI) bleeding 
due to gastric or duodenal ulceration, with signs of serious 
bleeding such as melena and/or hematemesis, were included 
in the study. An upper GI endoscopy was performed for 
diagnosis on the day of admission or the next day in patients 
with stable circulation. Emergency endoscopy was performed 
during nights and weekends only in patients with unstable 
circulation and with signs and symptoms of very serious 
bleeding. To prevent exclusion of patients with bleeding 
ulcers from the study due to miscoding, ie, those not recorded 
as having a bleeding ulcer, the records of all patients with the 
diagnosis of duodenal or gastric ulcer were reviewed.
Exclusion
Patients with bleeding from malignant ulcers, or   Dieulafoy’s 
or Mallory–Weiss lesions were excluded. Endoscopic, 
  surgical and laboratory data were retrospectively collected 
from the patients’ case records and were stored anonymously 
using a specially designed computer program. Three   two-year 
periods were studied, ie, 1985–1986 versus 2007–2008 and 
in addition 1995–1996, when testing and eradication of 
H. pylori was believed to have been established in this area 
after its introduction in Norway in 1992.
Diagnostic tests for Helicobacter pylori
Gastric biopsy for the detection of H. pylori was performed 
at the index endoscopy. If the test was negative or not 
  performed due to massive bleeding, the intention was to 
repeat the test procedure at a second ambulatory endoscopy, 
without any treatment with H2-antagonists or PPIs in the 
previous 10 days, to exclude a false-negative test at the index 
endoscopy. Both a positive urease rapid test within 24 hours 
and histologic verification were required for diagnosis of 
H. pylori infection.
hospital catchment population 
Every patient with acute GI bleeding in the hospital 
  catchment area was admitted to Haugesund Hospital in 
1985–1986 and 2007–2008. The   hospital catchment area 
did not change during this time. The total population in the 
catchment area had increased from 96,674 inhabitants in 
1985–1986 to 109,240 in 2007–2008. The total population 
and its age distribution for the three study time periods were 
obtained from the Norwegian   official statistics published on 
the Internet.13 The total annual incidence rates were calculated 
by using the mean number of patients with bleeding peptic 
ulcer versus the mean population in each two-year period. 
Two age groups, the first being 20–75 years and the second 
being older than 75 years, were selected to identify any dif-
ferences according to age.   Age-related incidence rates were 
calculated in parallel with the total incidence rates. Every 
registered patient was assumed to be under observation for 
one year in each study period. The rates were expressed per 
100,000 person-years of observation. Risk factors and other 
variables were   compared by χ2-test or Fisher’s exact test when 
appropriate. The recording of data and the calculations were 
performed with the Statistica program package (Statsoft Inc., 
Tulsa, OK).
Results
incidence
In total, 306 patients with bleeding duodenal or gastric ulcer 
were included during the three two-year study periods from 
January 1, 1985 to December 31, 2008. Incidence rates for all 
patients and for the two age groups are shown in Table 1. The 
total incidence rate of peptic ulcer bleeding in the   population 
did not differ significantly between the three time periods. 
In the age group 20–75 years, the incidence rate decreased 
by 54% between 1985–1986 and 2007–2008 (P = 0.001). In 
those patients older than 75 years, the incidence increased 
by 49% from the earliest to the last study time period 
(P = 0.0001). Demographic details of the patients, their 
previous history of peptic ulcer disease, dyspepsia, and 
hematemesis prior to admission for a bleeding ulcer are given 
in Table 2. The number of patients complaining of dyspepsia 
prior to ulcer bleeding decreased by 80% between 1985–1986 
and 2007–2008 (P = 0.0000 ).
risk factors for bleeding
Aspirin and nsAiDs
Use of drugs recognized as causing ulcers or known to 
  contribute to bleeding and the results of H. pylori testing 
are shown in Table 3. Findings at the index endoscopy Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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related to use or nonuse of aspirin and NSAID, ulcer size, 
and   bleeding activity according to time period are shown 
in Table 4. The ratio between duodenal and gastric ulcers 
(Du/Gu) was comparable between the time periods. The Du/
Gu ratio was twice as high in nonusers of aspirin or NSAIDs 
compared with users of these agents. The use of high- or 
low-dose aspirin or NSAIDs increased by 116% between 
1985–1986 and 2007–2008 (P = 0.004) and by 72% between 
1995–1996 and 2007–2008 (P = 0.03). In patients aged 
25–75 years, use of aspirin or NSAIDs increased by 103% 
between 1985–1986 and 2007–2008 (P = 0.06). In patients 
aged 75 years or older, use of aspirin or NSAIDs increased 
by 112% between 1985–1986 and 2007–2008 (P = 0.06). 
In 2007–2008 aspirin was coprescribed in addition to an 
NSAID in 14/37 (38%) patients, warfarin in 5/37 (14%), 
and steroids in 6/37 (16%), respectively. Nine of 32 (28%) 
of patients with a prior history of peptic ulcer disease used 
low-dose aspirin or NSAIDs in 2007–2008.
Tobacco and alcohol
Tobacco and alcohol use did not differ significantly when the 
three time periods were compared. Numbers of smokers and 
alcohol intake were small, although the information provided 
by patients on these issues may have been incorrect. The 
amount of alcohol intake was not recorded, but all patients 
included in this group had a period of heavy drinking prior 
to admission.
Other drugs
No patients were identified to have used clopidogrel as a 
single antiplatelet drug. A few patients in 2007–2008 may 
have used clopidogrel in addition to aspirin, but this was 
not recorded during the study. Concomitant intake of a PPI 
or H2-antagonist was not used by any patient at admission 
during any of the study time periods.
Helicobacter pylori
The result of H. pylori testing are shown in Table 3. In 
1995–1996, 84% of the tested patients were positive for H. 
pylori versus 52% in 2007–2008 (P = 0.06). In 1995–1996 
and in 2007–2008 H. pylori was confirmed in 73% and 51% 
of patients using aspirin or NSAIDs, respectively. In   nonusers 
of aspirin or NSAIDs, 89% had a positive H. pylori test in 
1995–1996 and 55% in 2007–2008. In 2007–2008, 10% of 
the patients were H. pylori negative and nonusers of low-dose 
aspirin or NSAIDs.
Discussion
incidence
The overall incidence of bleeding peptic ulcers in this study 
did not change from 1985–1986 (52/100000) to 2007–2008 
(46/100000) which is consistent with reports from Northern 
Europe,1,2 but in contrast with reports from Greece and Italy.3,4 
Penston et al5 reported a decrease in the incidence of peptic 
ulcer bleeding of 29% between 1981–1985 and 1986–1990 
Table 1 number of patients/population (incidencea) and age-adjusted incidence of peptic ulcer bleeding in a defined geographical area 
in norway during the time periods 1985–1986, 1995–1996, and 2007–2008
Time period 1985–1986 1995–1996 2007–2008 P value
Age (years)
$20 #75 66/60726 (54)1 69/63384 (54) 36/71096 (25)2 0.001 (1 vs 2)
75 33/6060 (272)1 39/6503 (300) 63/7754 (406)2 0.0001 (1 vs 2)
Total 101b/96674 (52)a  108/99294 (54) 99/109240 (45) ns
Notes: acases/100,000/year; btwo patients younger than 20 years (16 and 18 years) were included in 1985–1986.
Abbreviation: NS, not significant.
Table 2 Demographics, ulcer history, dyspepsia and hematemesis in patients admitted for peptic ulcer bleeding in the time periods 
1985–1986, 1995–1996, and 2007–2008
1985–1986 1995–1996 2007–2008 P value
Patients (n) 99 108 99
Male/female 49/50 67/41 54/45 ns
Mean age (95% Ci) 63 (59–66) 69 (65–73) 74 (70–78)
Previous ulcer 47 (47) 44 (41) 32 (32) ns
Previous bleeding ulcer 25 (25) 16 (15) 13 (13) ns
Previous perforated ulcer 4 (4) 1 (0.9) 3 (3) ns
Dyspepsia 59 (60)a 48 (44)b 12 (12)c 0.0000–0.0002
(a, b, vs c)
hematemesis 42 (42) 44 (41) 39 (39) ns
Abbreviations: CI, confidence interval; NS, not significant.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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in the community of Tayside in Scotland versus unchanged 
rates in Scotland overall, which was attributed to long-term 
H2-receptor antagonist treatment of peptic ulcer patients in 
Tayside. Long-term continuous treatment of peptic ulcer dis-
ease with H2 -receptor antagonists or PPIs has not been used 
to any extent in the area studied in Norway, but is unlikely to 
explain the unchanged incidence rate. Loperfido et al4 reported 
that the decline in the incidence rate of ulcer bleeding only 
occurred in people younger than 70 years of age, which is con-
sistent with the results of our present study, but the increased 
incidence in patients older than 75 years would account for 
the unchanged rate in this Norwegian population. No change 
in the number of patients with bleeding ulcers was reported 
from Australia between 1997 and 2007, and the patients 
Table 3 Oral use of aspirin or nsAiDs, drugs which may be related to bleeding, alcohol, tobacco, and Helicobacter pylori
1985–1986 1995–1996 2007–2008 P value
n = 99 n = 108 n = 99
high-dose aspirin1 18 (18)a 8 (7)b 1 (1)c 0.0001 (a vs c)
Low-dose aspirin2 1 (1)a 12 (11)b 37 (37)c 0.007–0.0000
nsAiDs3 12 (12)a 24 (22)b 42 (42)c 0.03–0.0003 (a, b, vs c)
Aspirin or nsAiDs 31 (31)a 42 (39)b 66 (67)c 0.004–0.03 (a, b, vs c)
Aspirin or nsAiDs
  20–75years 20/66 (30)a 22/69 (32)b 22/36 (61)c 0.06 (a vs c)
 . 75 years 11/33 (33)a 20/39 (51)b 44/63 (70)c 0.06 (a vs c)
Warfarin 0a 4 (4)b 18 (18)c 0.0000–0.002 (a, b vs c)
steroids 1 (1)a 9 (8)b 12 (12)c 0.02–0.003 (a vs b, c)
Alcohol 8 (8) 6 (6) 7 (7) ns
Tobacco 27 (27) 21 (19) 15 (15) ns
H. pylori tested 87 (81) 75 (76) ns
H. pylori positive 73 (84) 39 (52) 0.06
H. pylori positive
  Duodenal ulcer 51/62 (82) 27/47 (57) ns
  Gastric ulcer 22/25 (88) 12/28 (43) ns
H. pylori positive
  Aspirin or nsAiD users 22/30 (73) 28/55 (51) ns
  nonusers 51/57 (89) 11/20 (55) ns
Notes: 1Aspirin 0.5–1g; 2Aspirin 75–160 mg; 1,2,3Patients with simultaneous use of aspirin and nsAiD are recorded twice.
Abbreviations: NS, not significant; NSAID, nonsteroidal anti-inflammatory drug.
Table 4 Findings at the index endoscopy related to oral use or nonuse of aspirin or nsAiDs
1985–1986 1995–1996 2007–2008 P value
n = 99 n = 108 n = 99
Duodenal ulcer 52 (53) 72 (67) 58 (59)
Gastric ulcer 47 (47) 36 (33) 41 (41)
DU/GU ratio 1.1 2 1.4 ns
Aspirin or nsAiD users
  Duodenal ulcer 12 (23)a 24 (33)b 36 (62)c 0.01–0.06 (a, b vs c)
  Gastric ulcer 19 (40) 18 (50) 30 (73) ns
DU/GU ratio (users) 0.6 1.3 1.2
Aspirin or nsAiD nonusers
  Duodenal ulcer 40 (77)a 48 (67)b 22 (38)c 0.03–0.07 (a, b vs c)
  Gastric ulcer 28 (60)a 18 (50)b 11 (27)c 0.07 (a vs c)
DU/GU ratio (nonusers) 1.4 2.7 2
Ulcer size .2 cm 23 (23) 30 (28) 23 (23) ns
Bleeding activity (Forrest)
Arterial (F 1a) 4 (4) 5 (5) 5 (5) ns
Oozing (F 1b) 15 (15) 10 (9) 18 (18) ns
Visible vessel (F 2a) 2 (2) 3 (3) 7 (7) ns
Clot (F 2b) 9 (9) 5 (4)b 16 (16)c 0.02 (b vs c)
Black spot (F 2c) 2 (2)a 14 (13)b 26 (26)c 0.007–0.0000 (a vs b, c)
no signs (F 3) 67 (68)a 71 (66)b 27 (27)c 0.0006–0.0008 (a, b vs c)
Abbreviations: DU, duodenal ulcer; GU, gastric ulcer; NSAID, nonsteroidal anti-inflammatory drug.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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studied were also significantly older.14 This is consistent with 
the results of our study. In contrast, a population-based study 
by Lanas et al15   involving 10 hospitals in Spain reported a 
clear   decreasing trend in upper GI   admissions between 1996 
and 2005. This trend is consistent with other reports from 
southern Europe.3,4 The use of NSAIDs increased in the three 
studies from southern Europe,3,4,15 as was found in the pres-
ent study. The   different time trends in overall incidence rates 
between these studies3,4,15 and the present study may reflect a 
higher   prescription rate of H2-antagonists, PPIs, or H. pylori 
  eradication regimens in the populations in these countries 
than in the region of Norway studied here.
Aspirin and nsAiDs 
In the present study the increased use of aspirin or NSAIDs 
between 1985–1986 and 2007–2008, especially in the older 
patients, may be a major contributor to the increased inci-
dence of ulcer bleeding in those older than 75 years. Comor-
bidity and interactions with other drugs which increase the 
risk for bleeding eg, clopidogrel, may also contribute, report-
edly up to 45%.12 However, the use of aspirin or NSAIDs 
also increased in the younger age group between 1985–86 
and 2007–2008. The decline in the incidence of peptic ulcer 
bleeding in people younger than 75 years may be the result 
of a combination of favorable factors, eg, eradication of H. 
pylori, short-term treatment with H2-antagonists or PPIs, or 
a beneficial change in lifestyle factors in this age group. In 
2007–2008, 67% of the bleeding ulcers were attributed to 
or associated with aspirin or NSAIDs in this study, whereas 
other studies have reported rates of 46%–80%.1,3,4,12,14
Gastric/duodenal ulcer ratio
An increased Gu/Du ratio was expected when comparing 
the earlier and later time periods due to the increased use of 
aspirin or NSAIDs. This ratio did not change in accordance 
with the report by Ohmann et al.2 This may be explained by the 
low numbers of patients in each study period (Type II error). 
However, when users of aspirin or NSAIDs versus nonusers 
were compared, the ratio was about twice as high in each time 
period. The oral anticoagulant warfarin and low-dose aspirin 
were also coprescribed in the present study in 2007–2008 
which would increase the risk of serious ulcer bleeding.16
Dyspepsia
Dyspepsia prior to hospital admission decreased from 60% 
to 12% between 1985–1986 and 2007–2008 (P = 0.0000). 
  Dyspepsia is a major symptom in chronic peptic ulcer disease, 
and the increased frequency of patients without dyspeptic 
complaint prior to an ulcer bleeding is consistent with the 
findings of Gururatsakul et al and Henriksson et al.14,18 This 
change in symptom suggests an increased ratio of acute 
versus chronic ulcers caused by increased use of low-dose 
aspirin or NSAIDs.
Helicobacter pylori
The prevalence of H. pylori infection declined between 
1995–1996 and 2007–2008. The previously reported 
prevalence of H. pylori infection in 1998–1999 of about 
75%–80%17–19 is comparable with the prevalence seen in the 
present study in 1995–1996. The decline in prevalence of 
H. pylori infection in patients with bleeding ulcers between 
1995–1996 and 2007–2008 (P = 0.06), and also in nonusers 
of aspirin or NSAIDs, may be due to eradication of H. pylori 
in patients with uncomplicated peptic ulcer disease. The 
sensitivity of rapid urease testing and histology to detect 
H. pylori infection have been reported to be 0.67 and 0.70, 
respectively.20 The sensitivity of these two tests is assumed 
to have been similar in 1995–1996 and 2007–2008 in the 
present study. This may suggest a real decrease in H. pylori 
infection in patients with bleeding ulcers between 1995–1996 
and 2007–2008. The low proportion of patients tested for 
H. pylori especially in 2007–2008 creates a bias in the inter-
pretation of this time trend for H. pylori infection. The low 
percentage of patients tested presumably reflects   ongoing 
treatment with PPIs, both at the index and at a second endos-
copy where the ulcer may have been healed.
Helicobacter pylori, aspirin, nsAiDs
The combination of H. pylori infection and other risk factors, 
such as aspirin or NSAIDs, was high in the present study, 
being 73% and 51% in 1995–1996 and 2007–2008, respec-
tively. These three risk factors had an impact on the etiology of 
90% of bleeding peptic ulcers in the 2007–2008 study period. 
A study at Beograd21 identified that about 20% of patients 
with bleeding ulcers had none of these three risk factors, 
while Gisbert et al22 found that only 2% of patients developed 
bleeding ulcers in the absence of these risk factors. A study 
from Japan23 reported a corresponding prevalence of 11%, 
which is comparable with that in the present study. H. pylori, 
aspirin, and NSAIDs represent independent and synergistic 
risk factors both for uncomplicated peptic ulcer disease and 
for bleeding ulcers.23–26 Eradication of H. pylori is recom-
mended before NSAID therapy to reduce the risk for peptic 
ulcer disease.27,28 Eradication is also recommended before the 
start of low-dose aspirin prophylaxis.29–31 The results of the 
present study support both these recommendations.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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A limitation of this study is its retrospective design which 
may have introduced bias, eg, from absent data on previous 
ulcer disease, dyspepsia, oral use of other drugs which may 
induce or contribute to bleeding, anti-ulcer drugs, and use 
of tobacco and alcohol. To achieve the most reliable data, 
especially regarding the use of ulcerogenic drugs and other 
drugs which may contribute to bleeding, data were recorded 
from records at hospital admission, from previous hospital-
izations, and supplied or corrected with data recorded during 
the hospital stay and eventually at an ambulatory endoscopy 
after discharge from hospital. Estimation of ulcer size and 
classification of bleeding activity may be inaccurate due 
to the variable time lag between admission and the index 
endoscopy, as well as observer variation between endosco-
pists. Significant differences in findings for bleeding activity 
between the three time periods, ie, clot, black spot, and no 
signs (Table 4), need to be validated in future prospective 
studies. The low number of patients in each time period, 
especially for interpreting the results according to the two age 
groups, gives a low power in the statistical analyses and an 
increased likelihood of Type II error.
Conclusion
The overall incidence of bleeding peptic ulcers between 
1985–1986 and 2007–2008 remained unchanged in the 
population in this area of Norway. However, the incidence 
decreased by 54% in the age group 20–75 years and increased 
by 49% in those older than 75 years. The use of aspirin or 
NSAIDs prior to an ulcer bleeding increased from 31% to 
67% between 1985–1986 and 2007–2008. In 2007–2008, 
only 10% of the patients with peptic ulcer bleeding were 
nonusers of low-dose aspirin or NSAIDs and H. pylori nega-
tive. Dyspepsia prior to an emergency hospital admission for 
peptic ulcer bleeding declined from 60% to 12% in the same 
time period, which suggests an increasing frequency of acute 
bleeding ulcers caused by the use of ulcerogenic drugs.
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